efaroxan has been researched along with tizanidine in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Agbaba, D; Filipic, S; Nikolic, K | 1 |
| Honda, M; Kino, Y; Ono, H; Tanabe, M | 1 |
| Hashimoto, M; Ono, H; Tanabe, M | 1 |
3 other study(ies) available for efaroxan and tizanidine
| Article | Year |
|---|---|
QSAR study of imidazoline antihypertensive drugs.
Topics: Antihypertensive Agents; Binding Sites; Imidazoline Receptors; Imidazolines; Ligands; Models, Molecular; Molecular Structure; Quantitative Structure-Activity Relationship | 2008 |
Involvement of supraspinal imidazoline receptors and descending monoaminergic pathways in tizanidine-induced inhibition of rat spinal reflexes.
Topics: 5,6-Dihydroxytryptamine; Adrenergic Agents; Adrenergic alpha-Antagonists; Animals; Benzofurans; Clonidine; Dose-Response Relationship, Drug; Idazoxan; Imidazoles; Imidazoline Receptors; Male; Muscle Relaxants, Central; Norepinephrine; Oxidopamine; Rats; Rats, Wistar; Receptors, Drug; Reflex, Monosynaptic; Serotonin; Serotonin Agents; Spinal Cord; Sympathetic Nervous System; Time Factors | 2005 |
Imidazoline I(1) receptor-mediated reduction of muscle rigidity in the reserpine-treated murine model of Parkinson's disease.
Topics: Adrenergic alpha-Agonists; Adrenergic alpha-Antagonists; Animals; Antiparkinson Agents; Benzazepines; Benzofurans; Clonidine; Disease Models, Animal; Dose-Response Relationship, Drug; Electromyography; Idazoxan; Imidazoles; Imidazoline Receptors; Injections, Intraperitoneal; Ligands; Male; Mice; Muscle Rigidity; Muscle, Skeletal; Parkinsonian Disorders; Reserpine; Time Factors; Yohimbine | 2008 |